The Cancer and Leukemia Group B Respiratory Committee

Clinical Cancer Research

Volumn 12, Issue 11 II, 2006, Pages

  Vokes, Everett E ^a,e   Perry, Michael C ^b   Kindler, Hedy L ^a   Green, Mark R ^c,d  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF MISSOURI ST LOUIS   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d Network for Medical Communication and Research   (United States)

^e UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CELECOXIB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DIHYDROAZACYTIDINE; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; GEMCITABINE; HYDRAZINE SULFATE; LIPOXYGENASE INHIBITOR; METHOTREXATE; MITOMYCIN; NAVELBINE; NITROSOUREA DERIVATIVE; PACLITAXEL; PLACEBO; PLATINUM; PROTEIN TYROSINE KINASE INHIBITOR; RAZOXANE; TAMOXIFEN; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINDESINE; WARFARIN; ZILUETON;

BLEEDING; BONE MARROW SUPPRESSION; CHEMOTHERAPY; CLINICAL TRIAL; DRUG POTENTIATION; DRUG RESEARCH; ESOPHAGITIS; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG TOXICITY; MESOTHELIOMA; METHODOLOGY; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CLINICAL TRIALS; HUMANS; LEUKEMIA; LUNG NEOPLASMS; MESOTHELIOMA; NEOPLASMS; RADIOTHERAPY; SOCIETIES, MEDICAL;

EID: 33745195424     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-9015     Document Type: Review

References (64)

1. Green M, Horton C, Spaulding M, et al. Four-drug combination chemotherapy (methotrexate, cyclophosphamide, hexamethylmelamine, and CCNU) for non-small cell bronchogenic carcinoma: a Cancer and Leukemia Group B study. J Clin Oncol 1983;1:559-65.
2. Green MR, Kramar A, Schilsky R, et al. Platinum-based combination chemotherapy in advanced non-small cell lung cancer: a randomized phase II trial of the Cancer and Leukemia Group B. Med Pediatr Oncol 1990;18:197-202.
3. Vokes EE, Green MR. Clinical studies in non-small cell lung cancer: the CALGB experience. Cancer Invest 1998;16:72-9.
4. Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-report of a Canadian multicenter randomized trial. J Clin Oncol 1988;6:633-41.
5. Lilenbaum RC, Green MR. Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer. J Clin Oncol 1993;11:1391-402.
6. Kosty MP, Fleishman SB, Herndon JE II, et al. Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. J Clin Oncol 1994;12:1113-20.
7. Kosty MP, Herndon JE II, Green MR, et al. Placebo-controlled randomized study of hydrazine sulfate in lung cancer. J Clin Oncol 1995;13:1529-30.
8. Lilenbaum RC, Langenberg P, Dickersin K. Single agent versus combination chemotherapy in patients with advanced non-small cell lung carcinoma: a meta-analysis of response, toxicity, and survival. Cancer 1998;82:116-26.
9. Lilenbaum RC, Herndon JE II, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol 2005;23:190-6.
10. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
11. Sandler A, Gray R, Brahmer J, et al. Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial-E4599 [abstract 4]. J Clin Oncol 2005;23:1090s.
12. Edelman MJ, Wang X, Watson D, et al. Modulation in advanced non-small cell lung cancer (NSCLC): CALGB 30203. PASCO. In press 2006.
13. Isobe T, Herbst R, Onn A. Current management of advanced non-small cell lung cancer: targeted therapy. Semin Oncol 2005;32:315-28.
14. Herbst R, Prager D, Hermann R, et al. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-9.
15. Miller V, Kris M, Shah N. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004;22:1103-9.
16. Chen YM, Perng RP, Tsai CM. Gefitinib treatment is highly effective in non-small-cell lung cancer patients failing previous chemotherapy in Taiwan: a prospective phase II study. J Chemother 2005;17:679-84.
17. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993;328:184-94.
18. Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996;88:1210-5.
19. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990;323:940-5.
20. Sause W, Kolesar P, Taylor S, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer. Chest 2000;117:358-64.
21. Clamon G, Herndon J, Cooper R, et al. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 1999;17:4-11.
22. Vokes EE, Herndon JE, Kelley MJ, Watson D, Cicchetti MG, Green MR. Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC): initial analysis of a randomized phase III trial [abstract 7005]. Proc Am Soc Clin Oncol 2004;22:618s.
23. Vokes EE, Herndon JE II, Crawford J, et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B study 9431. J Clin Oncol 2002;20:4191-8.
24. Akerley W, Herndon JE, Jr., Lyss AP, et al. Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study-CALGB 9534. Clin Lung Cancer 2005;7:47-53.
25. Gervais R, Ducolone A, Lechevalier T, et al. Conventional radiation (RT) with daily carboplatin (Cb) compared with RT alone after induction chemotherapy (ICT) [vinorelbine (Vr)-cisplatin (P)]: final results of a randomized phase III trial in a stage III unresectable non small cell lung cancer (NSCLC) cancer. Study CRG/BMS/NPC/96 of the French Lung Cancer Study Group FNCLCC and IFCT [abstract 7016]. Proc Am Soc Clin Oncol 2005;23:625s.
26. Seiwert TY, Connell PP, Mauer AM, et al. A phase I dose-escalating study of combination pemetrexed-based chemotherapy and concomitant radiotherapy for locally advanced or metastatic non-small cell lung or esophageal cancer [abstract 7062]. J Clin Oncol (Meeting Abstracts) 2005;23:7062.
27. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected noon-small cell lung cancer. N Engl J Med 2005;352:2589-642.
28. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 2004;350:351-60.
29. Maurer LH, Pajak T, Eaton W, et al. Combined modality therapy with radiotherapy, chemotherapy, and immunotherapy in limited small-cell carcinoma of the lung. A Cancer and Leukemia Group B Phase III study. J Clin Oncol 1985;3:969-76.
30. Perry MC, Eaton WL, Propert KJ, et al. Chemotherapy with or without radiation therapy in limited small cell carcinoma of the lung: Cancer and Leukemia Group B Study 8083. N Engl J Med 1987;316:912-8.
31. Perry MC, Herndon JE II, Eaton WL, Green MR. Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B Study 8083. J Clin Oncol 1998;16:2466-7.
32. Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992;327:1618-24.
33. Arriagada R, Pignon JP, Ihde DC, et al. Effect of thoracic radiotherapy on mortality in limited small cell lung cancer. A meta-analysis of 13 randomized trials among 2,140 patients. Anticancer Res 1994;14:333-6.
34. Choi N, Propert K, Carey R, et al. Accelerated radiotherapy followed by chemotherapy for locally recurrent small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 1987;13:263-6.
35. Aisner J, Goutsou M, Maurer L, et al. Intensive combination chemotherapy, concurrent chest irradiation and warfarin for the treatment of limited disease small cell lung cancer: a CALGB pilot study. J Clin Oncol 1992;10:1230-6.
36. Kwiatkowski D, Propert KJ, Carey RW, et al. A phase II trial of cyclo-phosphamide, etoposide, and cisplatin with combined chest and brain radiotherapy in limited small-cell lung cancer: a Cancer and Leukemia Group B study. J Clin Oncol 1987;5:1874-9
37. Aisner J, Goutsou M, Maurer L, et al. Intensive combination chemotherapy, concurrent chest irradiation and warfarin for the treatment of limited disease small cell lung cancer: a CALGB pilot study. J Clin Oncol 1987;10:1230-6.
38. Chahinian AP, Propert KJ, Ware JH, et al. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol 1989;7:993-1002.
39. Choi NC, Herndon JE II, Rosenman J, et al. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated- accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol 1988;16:3528-36.
40. McClay EF, Bogart J, Herndon JE II, et al. A phase III trial evaluating the combination of cisplatin, etoposide and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B study 9235. Am J Clin Oncol 2005;28:81-90.
41. Spiegelman D, Maurer LH, Ware JH, et al. Prognostic factors in small-cell carcinoma of the lung: an analysis of 1,521 patients. J Clin Oncol 1989;7:344-54
42. North WG, Ware J, Maurer LH, Chahinian AP, Perry M. Neurophysins as tumor markers for small cell carcinoma of the lung: a Cancer and Leukemia Group B evaluation. Cancer 1988;62:1343-7.
43. Luikart SD, Herndon JE, Mollis DR, et al. Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung cancer: a Cancer and Leukemia Group B study (CALGB 8832). Am J Clin Oncol 1997;20:24-30.
44. Mitchell EP, Perry MC, Luikart SD, et al. A phase I/II trial of etoposide and cisplatin in extensive small cell lung cancer: a Cancer and Leukemia Group B study. Lung Cancer 1996;15:215-23.
45. Clamon G, Herndon J, Perry MC, et al. Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of Cancer and Leukemia Group B. J Natl Cancer Inst 1993;85:316-20.
46. Bitran JD, Green MR, Perry MC, Hollis DR, Herndon JE. for CALGB: a phase II study of recombinant IFN-γ as maintenance therapy following combination chemotherapy for patients with extensive small cell lung cancer. A role for biologic maintenance therapy? Am J Clin Oncol (CCT) 1995;18:67-70.
47. Neill HB, Herndon JE II, Miller AAA, et al. Randomized phase II intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factors in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group Trial 9732. J Clin Oncol 2005;23:3752-9.
48. Cella DF, Orofiamma B, Holland JC, et al. Relationship of psychological distress, extent of disease, and performance status in patients with lung cancer. Cancer 1987;60:1661-7.
49. Ahles TA, Silberfarb PM, Rundle AC, et al. Of life in patients with limited small-cell carcinoma of the lung receiving chemotherapy with or without radiation therapy, for Cancer and Leukemia Group B. Psychother Psychosom 1994;62:193-9.
50. Ahles TA, Silberfarb PM, Herndon J II, et al. Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: a study by the Cancer and Leukemia Group B. J Clin Oncol 1998;16:1954-60.
51. Chahinian AP, Antman K, Goutsou M, et al. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol 1993;11:1559-65.
52. Vogelzang N, Goutsou M, Corson J, et al. Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia group B. Cancer Chemother Pharmacol 1990;27:239-42.
53. Vogelzang NJ, Herndon II JE, Cirrincione C, et al. Dihydro-5-azacytidine in malignant mesothelioma: a phase II trial demonstrating activity but with cardiac toxicity. Cancer1997;79:2237-42.
54. Samuels BL, Herndon JE II, Harmon DC, et al. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Cancer 1998:82;1578-84.
55. Kindler HL, Millard F, Herndon JE II, et al. Gemcitabine for malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B. Lung Cancer 2001;31:311-7.
56. Vogelzang NJ, Herndon JE II, Miller A, et al. High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234. Ann Oncol 1999;10:597-600.
57. Kindler HL, Herndon JE, Zhang C, et al. Irinotecan for malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B Lung Cancer 2005;48:423-8.
58. Otterson GA, Herndon JE II, Watson D, et al. Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807). Lung Cancer 2004;44:251-9.
59. Kosty MP, Herndon JE II, Vogelzang NJ, et al. High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study Cancer and Leukemia Group B 9631. Lung Cancer 2001;34:289-95.
60. Vogelzang NJ, Weissman LB, Herndon JE II, et al. Trimetrexate in malignant mesothelioma: a Cancer and Leukemia Group B Phase II study. J Clin Oncol 1994;12:1436-42.
61. Kindler HL, Belani CP, Herndon JE II, et al. Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the Cancer and Leukemia Group B. Cancer 1999;86:1985-91.
62. Herndon JE, Green MR, Chahinian AP, et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998;113:723-31.
63. Govindan R, Kratzke RA, Herndon JE II, et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group 6. Clin Cancer Res 2005;11:2300-4.
64. Jahan TM, Gu L, Wang X, et al. Vatalanib in patients with previously untreated advanced malignant mesothelioma (MM): preliminary analysis of a phase II study by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer 2005;49 Supplement 2:S222.